Shanghai Fosun Pharmaceutical Stock Debt To Equity
| SFOSFDelisted Stock | USD 1.70 0.00 0.00% |
Shanghai Fosun Pharmaceutical fundamentals help investors to digest information that contributes to Shanghai Fosun's financial success or failures. It also enables traders to predict the movement of Shanghai Pink Sheet. The fundamental analysis module provides a way to measure Shanghai Fosun's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Fosun pink sheet.
Shanghai |
Shanghai Fosun Pharmaceutical Company Debt To Equity Analysis
Shanghai Fosun's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Shanghai Fosun Debt To Equity | 0.64 % |
Most of Shanghai Fosun's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Fosun Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Shanghai Fosun Pharmaceutical has a Debt To Equity of 0.64%. This is 98.8% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The debt to equity for all United States stocks is 98.69% higher than that of the company.
Shanghai Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Fosun's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Fosun could also be used in its relative valuation, which is a method of valuing Shanghai Fosun by comparing valuation metrics of similar companies.Shanghai Fosun is currently under evaluation in debt to equity category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.0756 | |||
| Return On Asset | 0.0204 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 15.52 B | |||
| Shares Outstanding | 551.94 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 35.60 % | |||
| Price To Earning | 13.80 X | |||
| Price To Book | 1.45 X | |||
| Price To Sales | 0.31 X | |||
| Revenue | 39.01 B | |||
| Gross Profit | 18.71 B | |||
| EBITDA | 8.71 B | |||
| Net Income | 4.74 B | |||
| Cash And Equivalents | 14.64 B | |||
| Cash Per Share | 5.49 X | |||
| Total Debt | 9.05 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.00 X | |||
| Book Value Per Share | 16.30 X | |||
| Cash Flow From Operations | 3.95 B | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 36.28 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 12.25 B | |||
| Total Asset | 93.29 B | |||
| Retained Earnings | 10.37 B | |||
| Working Capital | (817 M) | |||
| Current Asset | 10.27 B | |||
| Current Liabilities | 11.09 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 93.29 B | |||
| Last Dividend Paid | 0.56 |
About Shanghai Fosun Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Fosun Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Fosun using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Fosun Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Shanghai Pink Sheet
If you are still planning to invest in Shanghai Fosun Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shanghai Fosun's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |